PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 2869632-0 1986 Somatostatin, insulin and glucagon after arginine stimulation in active and treated acromegaly. Arginine 41-49 somatostatin Homo sapiens 0-12 1355580-2 1992 The aim of our study was to verify whether arginine ([Arg] 30 g intravenously [IV] in 30 minutes), a well-known GH secretagogue likely acting via inhibition of hypothalamic somatostatin release, counteracts the inhibitory effect of oral glucose (OG) administration (100 mg orally) on the GH response to GHRH (1 micrograms/kg IV bolus) in seven normal subjects (aged 20 to 30 years). Arginine 43-51 somatostatin Homo sapiens 173-185 1355580-2 1992 The aim of our study was to verify whether arginine ([Arg] 30 g intravenously [IV] in 30 minutes), a well-known GH secretagogue likely acting via inhibition of hypothalamic somatostatin release, counteracts the inhibitory effect of oral glucose (OG) administration (100 mg orally) on the GH response to GHRH (1 micrograms/kg IV bolus) in seven normal subjects (aged 20 to 30 years). Arginine 54-57 somatostatin Homo sapiens 173-185 35286077-1 2022 In an effort to develop precursors for the production of lanthanide silicate (LnSiOx) materials, the reactions of (Ln(NR2)3) (R = SiMe3) with three equivalents of tris(trimethylsilyl)silanol (H-OSi(SiMe3)3) or H-SST) in tetrahydrofuran (THF) were undertaken. Arginine 126-127 somatostatin Homo sapiens 212-215 2564394-0 1989 Characterization of an endoprotease from rat small intestinal mucosal secretory granules which generates somatostatin-28 from prosomatostatin by cleavage after a single arginine residue. Arginine 169-177 somatostatin Homo sapiens 105-120 8094610-2 1993 To look for a possible functional correlate to this finding basal and arginine stimulated plasma somatostatin and serum C peptide concentrations in eight insulin treated patients with cystic fibrosis and eight normal male controls were measured. Arginine 70-78 somatostatin Homo sapiens 97-109 6146518-0 1984 Effect of Ala-2-D-Trp-8-D-Cys-14-somatostatin on the arginine induced release of insulin, GH and glucagon in normal men. Arginine 53-61 somatostatin Homo sapiens 33-45 6148165-0 1984 Arginine infusion increases peripheral plasma somatostatin in man. Arginine 0-8 somatostatin Homo sapiens 46-58 6142577-0 1984 Arginine hydrochloride stimulation of serum potassium and aldosterone is enhanced by somatostatin-28. Arginine 0-22 somatostatin Homo sapiens 85-100 6142577-6 1984 SS-28 completely inhibited the arginine-stimulated insulin increase while SS-14 only partially inhibited the insulin increase. Arginine 31-39 somatostatin Homo sapiens 0-5 6142577-7 1984 Since insulin opposes the increase in serum potassium by stimulating cellular uptake of this cation, the enhanced rise in serum potassium in response to arginine hydrochloride during the SS-28 infusion is likely due to the potent insulin suppressing effect of SS-28. Arginine 153-175 somatostatin Homo sapiens 187-192 6142577-7 1984 Since insulin opposes the increase in serum potassium by stimulating cellular uptake of this cation, the enhanced rise in serum potassium in response to arginine hydrochloride during the SS-28 infusion is likely due to the potent insulin suppressing effect of SS-28. Arginine 153-175 somatostatin Homo sapiens 260-265 6146518-1 1984 The effects of several doses of somatostatin (SS) and the analog Ala-2-D-Trp-8-D-Cys-14-SS on the arginine-induced release of insulin, glucagon, and GH were compared in a group of normal human subjects. Arginine 98-106 somatostatin Homo sapiens 32-44 6137927-2 1983 Arginine administered at 30-60 min induced an increase in plasma glucose concentrations which was enhanced by SS-14 and further increased by SS-28. Arginine 0-8 somatostatin Homo sapiens 110-115 6137927-2 1983 Arginine administered at 30-60 min induced an increase in plasma glucose concentrations which was enhanced by SS-14 and further increased by SS-28. Arginine 0-8 somatostatin Homo sapiens 141-146 6137927-3 1983 SS-28 was more effective than SS-14 in suppressing the arginine-induced secretion of insulin. Arginine 55-63 somatostatin Homo sapiens 0-5 6137927-3 1983 SS-28 was more effective than SS-14 in suppressing the arginine-induced secretion of insulin. Arginine 55-63 somatostatin Homo sapiens 30-35 6137927-4 1983 Arginine-stimulated and insulin-stimulated (at 120 min) glucagon release was equally suppressed by SS-14 and SS-28, as was insulin-stimulated pancreatic polypeptide secretion. Arginine 0-8 somatostatin Homo sapiens 99-104 6137927-4 1983 Arginine-stimulated and insulin-stimulated (at 120 min) glucagon release was equally suppressed by SS-14 and SS-28, as was insulin-stimulated pancreatic polypeptide secretion. Arginine 0-8 somatostatin Homo sapiens 109-114 6112138-1 1981 Somatostatin-28 (SS-28) is 380 times as potent as somatostatin-14 (SS-14) to inhibit acutely insulin secretion induced by arginine in vivo; SS-28 is only 3 times as potent as SS-14 to inhibit glucagon secretion induced by arginine. Arginine 122-130 somatostatin Homo sapiens 0-15 6134596-0 1983 Somatostatin-28 and somatostatin-14 suppression of arginine-, insulin-, and TRH-stimulated GH and PRL secretion in man. Arginine 51-59 somatostatin Homo sapiens 20-35 6134596-4 1983 Arginine (0.5 g/kg) infused from 30 to 60 min induced an increase in GH secretion in all subjects and this increase was completely abolished in these same subjects when infused with SS-14 and SS-28. Arginine 0-8 somatostatin Homo sapiens 182-187 6134596-4 1983 Arginine (0.5 g/kg) infused from 30 to 60 min induced an increase in GH secretion in all subjects and this increase was completely abolished in these same subjects when infused with SS-14 and SS-28. Arginine 0-8 somatostatin Homo sapiens 192-197 6134596-5 1983 Arginine-induced hyperglycaemia was significantly greater during infusion of SS-14 and further enhanced by infusion of SS-28. Arginine 0-8 somatostatin Homo sapiens 77-82 6134596-5 1983 Arginine-induced hyperglycaemia was significantly greater during infusion of SS-14 and further enhanced by infusion of SS-28. Arginine 0-8 somatostatin Homo sapiens 119-124 6112138-1 1981 Somatostatin-28 (SS-28) is 380 times as potent as somatostatin-14 (SS-14) to inhibit acutely insulin secretion induced by arginine in vivo; SS-28 is only 3 times as potent as SS-14 to inhibit glucagon secretion induced by arginine. Arginine 122-130 somatostatin Homo sapiens 17-22 6112138-1 1981 Somatostatin-28 (SS-28) is 380 times as potent as somatostatin-14 (SS-14) to inhibit acutely insulin secretion induced by arginine in vivo; SS-28 is only 3 times as potent as SS-14 to inhibit glucagon secretion induced by arginine. Arginine 122-130 somatostatin Homo sapiens 50-65 6112138-1 1981 Somatostatin-28 (SS-28) is 380 times as potent as somatostatin-14 (SS-14) to inhibit acutely insulin secretion induced by arginine in vivo; SS-28 is only 3 times as potent as SS-14 to inhibit glucagon secretion induced by arginine. Arginine 122-130 somatostatin Homo sapiens 67-72 6112138-1 1981 Somatostatin-28 (SS-28) is 380 times as potent as somatostatin-14 (SS-14) to inhibit acutely insulin secretion induced by arginine in vivo; SS-28 is only 3 times as potent as SS-14 to inhibit glucagon secretion induced by arginine. Arginine 222-230 somatostatin Homo sapiens 0-15 6112138-2 1981 D-Trp substitution in position 28 of SS-28 increase potency to 2600 times that of SS-14 for inhibition of arginine induced insulin secretion. Arginine 106-114 somatostatin Homo sapiens 37-42 6112138-2 1981 D-Trp substitution in position 28 of SS-28 increase potency to 2600 times that of SS-14 for inhibition of arginine induced insulin secretion. Arginine 106-114 somatostatin Homo sapiens 82-87 6109991-2 1981 The effects of the hypothalamic 28 aminoacid peptide prosomatostatin (Pro-SS) on arginine-induced growth hormone (GH) and prolactin (PRL) release and blood glucose levels in man are compared with those obtained after an equimolar dose of somatostatin (SS). Arginine 81-89 somatostatin Homo sapiens 56-68 6108171-7 1980 Arginine-stimulated insulin and growth hormone (hGH) concentrations were considerably lowered by the somatostatin infusion. Arginine 0-8 somatostatin Homo sapiens 101-113 409475-0 1977 Effect of somatostatin on thyrotropin, prolactin, growth hormone and insulin responses to thyrotropin releasing hormone and arginine in healthy, hypothyroid and acromegalic subjects. Arginine 124-132 somatostatin Homo sapiens 10-22 219013-1 1979 The inhibition by somatostatin (SRIF) of basal and arginine-stimulated glucagon, insulin, and glucose levels was compared with that obtained when SRIF was preceded by alpha-adrenergic blockade with phentolamine. Arginine 51-59 somatostatin Homo sapiens 18-30 897837-3 1977 Arginine, presumably via insulin release, caused a fall in free fatty acids (FFA) in controls, which was inhibited by somatostatin. Arginine 0-8 somatostatin Homo sapiens 118-130 870515-7 1977 Somatostatin abolished IRI and GH responses to arginine in both groups studied (P less than 0.001). Arginine 47-55 somatostatin Homo sapiens 0-12 870353-4 1977 Somatostatin, at three different dosages, markedly influenced these patterns: HGH response to arginine was suppressed by the lowest somatostatin dose; IRG response was progressively inhibited by increasing doses of somatostatin but never reached zero; cortisol level was not decreased but slightly increased by somatostatin. Arginine 94-102 somatostatin Homo sapiens 0-12 870353-4 1977 Somatostatin, at three different dosages, markedly influenced these patterns: HGH response to arginine was suppressed by the lowest somatostatin dose; IRG response was progressively inhibited by increasing doses of somatostatin but never reached zero; cortisol level was not decreased but slightly increased by somatostatin. Arginine 94-102 somatostatin Homo sapiens 132-144 870353-5 1977 Substrate responses to arginine were also modified by somatostatin: alanine disappearance was impaired, this effect being dose-related; plasma FFA and 3-hydroxybutyrate concentrations showed a significant increase rather than decrease, consistent with somatostatin suppression of residual insulin secretion. Arginine 23-31 somatostatin Homo sapiens 54-66 870353-5 1977 Substrate responses to arginine were also modified by somatostatin: alanine disappearance was impaired, this effect being dose-related; plasma FFA and 3-hydroxybutyrate concentrations showed a significant increase rather than decrease, consistent with somatostatin suppression of residual insulin secretion. Arginine 23-31 somatostatin Homo sapiens 252-264 1138156-2 1975 In normal subjects 150 mug of somatostatin completly suppressed GH and IRI responses to arginine, while with 75 and 37.5 mug only a partial suppression was usually observed. Arginine 88-96 somatostatin Homo sapiens 30-42 9753390-2 1998 The importance of the residues located near the Arg-Lys dibasic site in the C-terminal region of the pro-hormone for the cleavage of the precursor into somatostatin-14 has been confirmed. Arginine 48-51 somatostatin Homo sapiens 152-167 1092707-4 1975 Similarly, the addition of somatostatin infusion completely blocked the release of insulin and growth hormone and delayed the release of glucagon stimulated by arginine infusion. Arginine 160-168 somatostatin Homo sapiens 27-39 1092707-5 1975 Following the somatostatin infusion there was a small rise in GH and a marked rebound for insulin and this was associated with a higher level of plasma glucose than that found following arginine infusion alone. Arginine 186-194 somatostatin Homo sapiens 14-26 1092707-6 1975 These data establish that the administration of somatostatin can effectively block the release of insulin stimulated by arginine and glucose, can attenuate the release of glucagon induced by arginine and can enhance the glucose-mediated glucagon suppression. Arginine 120-128 somatostatin Homo sapiens 48-60 1092707-6 1975 These data establish that the administration of somatostatin can effectively block the release of insulin stimulated by arginine and glucose, can attenuate the release of glucagon induced by arginine and can enhance the glucose-mediated glucagon suppression. Arginine 191-199 somatostatin Homo sapiens 48-60 10594405-9 1999 L-Arg did not affect postprandial pH and plasma hormones, but reversed L-NMMA-induced alterations in intragastric pH and in plasma gastrin and somatostatin levels. Arginine 0-5 somatostatin Homo sapiens 143-155 22495673-3 2012 The aspartic acid changes at position 89 to either Ala, Leu, or Arg generated mutant receptors with varying expression profiles and a complete inability to bind somatostatin-14 (SST). Arginine 64-67 somatostatin Homo sapiens 161-176 22495673-3 2012 The aspartic acid changes at position 89 to either Ala, Leu, or Arg generated mutant receptors with varying expression profiles and a complete inability to bind somatostatin-14 (SST). Arginine 64-67 somatostatin Homo sapiens 178-181 22495673-4 2012 Mutations to Asp 139 and Arg 140 also led to varying expression profiles with some mutants maintaining their affinity for SST. Arginine 25-28 somatostatin Homo sapiens 122-125 11814357-9 2002 Moreover, they emphasize the importance of the S-28(1-12) segment joining Arg(-15) and Arg(-2)Lys(-1) cleavage sites whose conformational organization is essential for controlling their accessibility to the appropriate processing proteases. Arginine 74-77 somatostatin Homo sapiens 47-51 11814357-9 2002 Moreover, they emphasize the importance of the S-28(1-12) segment joining Arg(-15) and Arg(-2)Lys(-1) cleavage sites whose conformational organization is essential for controlling their accessibility to the appropriate processing proteases. Arginine 87-90 somatostatin Homo sapiens 47-51 10071480-0 1999 L-arginine stimulates NO-dependent vasodilation in healthy humans--effect of somatostatin pretreatment. Arginine 0-10 somatostatin Homo sapiens 77-89 7788012-5 1995 In conclusion, the neuroregulation of GH release seems to be similar qualitatively in normal-weight and obese youngsters; the different behavior observed after arginine, which is supposed to act through somatostatin inhibition, might be due to a chronic increase in somatostatinergic tone responsible for the lower stimulated GH levels in obesity. Arginine 160-168 somatostatin Homo sapiens 203-215